

Supplemental Material

Bisphenol A and Reproductive Health: Update of Experimental and Human Evidence, 2007–2013

Jackye Peretz, Lisa Vrooman, William A. Ricke, Patricia A. Hunt, Shelley Ehrlich, Russ Hauser, Vasantha Padmanabhan, Hugh S. Taylor, Shanna H. Swan, Catherine A. VandeVoort, and Jodi A. Flaws

| Table of Contents | Page |
|---|-------------|
| Table S1. BPA, ovarian and oviductal outcomes, and steroidogenesis in experimental studies | 2 |
| Table S2. BPA and female human reproductive outcomes | 6 |
| Table S3. BPA and uterine outcomes in experimental studies | 10 |
| Table S4. BPA and human pregnancy and birth outcomes | 13 |
| Table S5. BPA and pregnancy outcomes in experimental studies | 16 |
| Table S6. BPA and male human reproductive outcomes | 18 |
| Table S7. BPA and male reproductive outcomes in experimental studies | 20 |
| Table S8. BPA and sexual function outcomes in experimental studies | 25 |
| References | 27 |

Table S1. BPA, ovarian and oviductal outcomes, and steroidogenesis in experimental studies.

| Source | Animal | Strain | Exposure route | Time of exposure | Doses | Age at collection | Outcome |
|----------------------------------|--------|------------|--|--------------------------------------|------------------------|-------------------|---|
| Adewale et al. 2009 | Rat | Long-Evans | Subcutaneous injection | Neonatal exposure: PND0-PND3 | 50µg/kg and 50mg/kg | PND148 | Disrupted ovarian development |
| Berger et al. 2008 | Mouse | CF-1 | Subcutaneous injection | Gestational exposure: GD1-GD4 | 0.01-300mg/kg | GD6 | Decreased number of implantation sites, decreased progesterone |
| Berger et al. 2008 | Mouse | CF-1 | Subcutaneous injection | Gestational exposure: GD0,1, or 2 | 200 and 300mg/kg | GD6 | Decreased number of implantation sites, decreased progesterone |
| Berger et al. 2010 | Mouse | CF-1 | Subcutaneous injection | Gestational exposure: GD1-GD4 | 100, 200, 300mg/kg | GD6 | Altered estrogen receptor and progesterone gene expression |
| Briño-Enriquez et al. 2011a | Human | NA | <i>In vitro</i> ; Fetal oocytes | 7, 14, 21 days | 1, 5, 10, 20, 30µM | 18-22 weeks old | Oocyte degeneration, impaired meiosis |
| Briño-Enriquez et al. 2011b | Human | NA | <i>In vitro</i> ; Fetal oocytes | 7, 14, 21 days | 30µM | 18- 22 weeks old | Increased oocyte DNA double strand break, signaling, and repair genes |
| Chao et al. 2012 | Mouse | CD-1 | Subcutaneous injection | Neonatal exposure: PND7-PND14 | 20, 40µg/kg | PND15 | Impaired methylation of imprinted genes during oogenesis, increases primordial follicular recruitment |
| Chao et al. 2012 | Mouse | CD-1 | Subcutaneous injection | Neonatal exposure: PND5,10,15,20 | 20, 40µg/kg | PND21 | Impaired methylation of imprinted genes during oogenesis, increases primordial follicular recruitment |
| Eichenlaub-Ritter et al. 2008 | Mouse | MF1 | <i>In vitro</i> ; Prepubertal oocytes | 16 hours | 0.22-43.8µM | After culture | Impaired meiosis, increased meiotic arrest, normal GVBD |
| Eichenlaub-Ritter et al. 2008 | Mouse | MF1 | Oral gavage | Neonatal exposure: PND22-PND28 | 20, 40, 100ng/g | PND28 | Impaired meiosis, increased meiotic arrest, normal GVBD |

| Source | Animal | Strain | Exposure route | Time of exposure | Doses | Age at collection | Outcome |
|-----------------------|-------------------|-------------------|---|---|---------------------------------------|-------------------------|--|
| Fernandez et al. 2010 | Rat | Sprague-Dawley | Subcutaneous injection | Neonatal exposure: PND1-PND10 | 5µg/50µL, 50µg/50µL, 500µg/50µL | 4-5 months old | Increased testosterone and estradiol, increased follicular cysts, increased infertility |
| Grasseli et al. 2010 | Pig | NA | <i>In vitro</i> , granulosa cells | 48 hours | 0, 0.1, 1, 10µM | NA | Altered steroidogenesis, increased VEGF |
| Hunt et al. 2012 | Non-human primate | Rhesus macaque | Dietary exposure | Gestational exposure: GD50-GD100 | 400µg/kg | GD100 | Impaired meiosis, increased multi-oocyte follicles, increased unenclosed and non-growing oocytes |
| Hunt et al. 2012 | Non-human primate | Rhesus macaque | Dietary exposure | Gestational exposure: GD100-term | 400µg/kg | PND0 | Impaired meiosis, increased multi-oocyte follicles, increased unenclosed and non-growing oocytes |
| Hunt et al. 2012 | Non-human primate | Rhesus macaque | Silastic pump | Gestational exposure: GD50-GD100 | 2.2-3.3ng/mL serum levels | GD100 | Impaired meiosis, increased multi-oocyte follicles, increased unenclosed and non-growing oocytes |
| Hunt et al. 2012 | Non-human primate | Rhesus macaque | Silastic pump | Gestational exposure: GD100-term | 2.2-3.3ng/mL serum levels | PND0 | Impaired meiosis, increased multi-oocyte follicles, increased unenclosed and non-growing oocytes |
| Kobayashi et al. 2012 | Rat | Sprague-Dawley | Dietary exposure | Gestational and neonatal exposure: GD6-PND21 | 0, 0.33, 3.3, and 33 ppm | 5 weeks or 3 months old | No change in hormones, AGD, lower ovarian weight |
| Lawson et al. 2011 | Mouse | C57BL/6 | Oral exposure | Gestational exposure: GD11-GD14.5 | 20ng/g | GD12, 12.5, 13.5, 14.5 | Disrupted oogenesis via meiotic gene expression alterations |
| Lee SG et al. 2013 | Rat | Sprague-Dawley | Oral gavage | Postnatal exposure: 90 days | 0.001 and 0.1mg/kg | 21 weeks old | Decreased testosterone and estradiol, increased atresia |
| Lenie et al. 2008 | Mouse | C57BL/6j x CBA/Ca | <i>In vitro</i> : Early preantral follicles | 12 days | 3nM-30µM | NA | Impaired meiosis, impaired follicle development |
| Li Y et al. 2013 | Rat | Wistar | Intraperitoneal injection | Neonatal exposure: 7 days | 10, 40, 160mg/kg | 35 days old | Decreased follicle numbers, increased atretic follicles |

| Source | Animal | Strain | Exposure route | Time of exposure | Doses | Age at collection | Outcome |
|-------------------------------|--------|----------------|-----------------------------------|--|-------------------------------|-----------------------------|--|
| Machtinger et al. 2013 | Human | NA | <i>In vitro</i> : Adult oocytes | 30 hours | 20, 200ng/ml, 20µg/ml | Immature (GV stage) oocytes | Increased meiotic arrest, disrupted spindle formation and chromosome alignment, increased spontaneous oocyte activation |
| Mendoza-Rodriguez et al. 2011 | Rat | Wistar | Drinking water | Gestational and neonatal exposure: GD6-PND21 | 10mg/L (1.2mg/kg) | 7 weeks old | Increased uterine epithelial and stromal thickness, decreased uterine epithelial apoptosis, downregulation of <i>Esr1</i> expression in epithelial cells |
| Newbold et al. 2009 | Mouse | CD-1 | Subcutaneous injection | Gestational exposure: GD9-GD16 | 0, 0.1, 1, 10, 100, 1000µg/kg | 18 months old | Induced ovarian cystadenomas, induced progressive proliferative oviductal lesions |
| Pacchierotti et al. 2008 | Mouse | C57BL/6 | Oral gavage | Postnatal exposure: Single dose | 0.2 and 20mg/kg | 4-11 weeks old | No effect on meiotic abnormalities |
| Pacchierotti et al. 2008 | Mouse | C57BL/6 | Oral gavage | Postnatal exposure: Single dose | 0.04mg/kg | 4-11 weeks old | No effect on meiotic abnormalities |
| Pacchierotti et al. 2008 | Mouse | C57BL/6 | Drinking water | Postnatal exposure: 7 weeks | 0.5mg/L | 4-11 weeks old | No effect on meiotic abnormalities |
| Peretz et al. 2012 | Mouse | CD-1 | <i>In vitro</i> :Antral follicles | 24-96 hours | 4.4-440µM | 32-35 day old mice | Inhibited follicle growth, induced atresia, dysregulated cell cycle |
| Peretz et al. 2011 | Mouse | FVB | <i>In vitro</i> :Antral follicles | 24-120 hours | 4.4-440µM | 32-35 day old mice | Inhibited follicle growth, inhibited steroidogenesis |
| Rivera et al. 2011 | Lamb | Hampshire Down | Subcutaneous injection | Neonatal exposure: PND1-PND14 | 50µg/kg | PND1, 5, 10, 30 | Increased primordial follicular recruitment, increased multi-oocyte follicles, increased granulosa and theca cell proliferation, induced atresia |
| Rodríguez et al. 2010 | Rat | Wistar | Subcutaneous injection | Neonatal exposure: PND1-PND7 | 0.05 and 20mg/kg | PND8 | Increased primordial follicular recruitment, increased granulosa cell proliferation |
| Signorile et al. 2010 | Mouse | Balb-c | Subcutaneous injection | Gestational exposure: GD1-PND7 | 100 and 1000µg/kg | 3 months old | Induced endometriosis-like phenotype |

| Source | Animal | Strain | Exposure route | Time of exposure | Doses | Age at collection | Outcome |
|-------------------------|--------|-----------------|---|--------------------------------------|--|-------------------------------|--|
| Tan et al. 2013 | Mouse | ICR | Oral gavage | Gestational exposure: E13-E16 | 2, 20, 200mg/kg | E17 | Increased estradiol, testosterone, and corticotropin releasing hormone |
| Trapphoff et al. 2013 | Mouse | C57BL/6x CBA/Ca | <i>In vitro</i> : Pre-antral follicles | 12 days | 3 and 300nM | 12-14 days old | Accelerated follicle development, disrupted genomic imprinting |
| Varayoud et al. 2011 | Rat | Wistar | Subcutaneous injection | Neonatal exposure: PND1, 3, 5, and 7 | 0.05 and 20mg/kg | F1: GD5 or GD18 | Down-regulated estrogen receptor and progesterone receptor |
| Veiga-Lopez et al. 2013 | Lamb | Suffolk | Subcutaneous injection | Gestational exposure: GD30-GD90 | 0.5mg/kg | GD60 and GD90 | Altered steroidogenic and miRNA gene expression |
| Xi et al. 2011 | Mouse | CD-1 | Oral gavage | Postnatal exposure, F0: GD1-PND20 | 12, 25, 50mg/kg | PND50 | Disrupted feedback circuits of hypothalamic-pituitary-gonad axis |
| Xi et al. 2011 | Mouse | CD-1 | Oral gavage | Postnatal exposure, F1: PND21-PND49 | 12, 25, 50mg/kg | PND50 | Disrupted feedback circuits of hypothalamic-pituitary-gonad axis |
| Xi et al. 2011 | Mouse | CD-1 | Oral gavage | Postnatal exposure, F1: PND21-PND49 | 25 and 50mg/kg | PND50 | Disrupted feedback circuits of hypothalamic-pituitary-gonad axis |
| Zhang H et al. 2012 | Mouse | CD-1 | Oral exposure | Gestational exposure: GD12.5-PND18.5 | 0, 0.2, 0.04, 0.08mg/kg | GD15.5, 17.5, 19.5 PND3, 5, 7 | Inhibits meiosis, impairs germ cell nest breakdown |
| Zhang X et al. 2012 | Mouse | CD-1 | Oral exposure | Gestational exposure: GD0.5-PND0 | 0, 40, 80, 160µg/kg | PND0 | Altered methylation and expression of imprinting genes |
| Zhou et al. 2008 | Rat | Sprague-Dawley | <i>In vitro</i> : Isolated follicular cells | 72 hours | 10 ⁻⁴ to 10 ⁻⁷ M | 30 days old | Altered steroidogenic enzyme expression and steroidogenesis |
| Ziv-Gal et al. 2013 | Mouse | C57BL/6 | <i>In vitro</i> : Antral follicles | 96 hours | 0.004 to 438µM | 54-58 days old | Inhibited follicle growth, inhibited estradiol levels |

AGD=anogenital distance; ESR1=estrogen receptor 1; F1=first filial generation; GD=gestation day; GV=germinal vesicle; GVBD=germinal vesicle breakdown; NA=not applicable; PND=postnatal day

Table S2. BPA and female human reproductive outcomes.

| Source | Study design | Study population | Sample size | Timing of BPA measurement | BPA concentration (mean, geometric mean or median) | Outcome | Comments/limitations |
|------------------------|--------------------|---|--|---|---|--|---|
| Bloom et al. 2011a | Cross-sectional | Women undergoing IVF (University of California-San Francisco) | 44 | Preconception (day of egg retrieval) | Median: 2.53ng/mL serum (unconjugated) | Negative association of BPA with peak estradiol (β -0.16, 95% CI: -0.32, 0.01); null association with # oocytes retrieved (aRR: 0.95, 95% CI: 0.827, 1.10) | Small sample size, BPA measured once per treatment cycle |
| Bloom et al. 2011b | Prospective cohort | Couples undergoing IVF (University of California-San Francisco) | 27 couples (36 women) | Preconception (day of egg retrieval) | Median: 3.3ng/ml (women) 85% detection rate vs. 0.48ng/mL (men) 53% detection rate, serum (unconjugated) | Negative association between male BPA and embryo quality (aOR: 0.54, p = 0.009) and normal embryo cleavage rate (aOR: 0.70, p = 0.07); null association of female BPA and embryo quality | Small sample size, BPA measured once, larger than expected difference in median serum BPA in men and women |
| Buck Louis et al. 2013 | Matched cohort | Women undergoing laparoscopy/laparomy | 495 individuals in operative cohort and 131 women in population cohort | At the time of laparoscopy/ screening for endometriosis | Geometric mean for operative cohort: 1.45 (1.14-1.84) ng/ml for women with endometriosis and 1.66 (1.40-1.97) ng/ml for women without endometriosis; geometric mean for population cohort: 4.19 (2.18-8.03) ng/ml for women with endometriosis and 1.65 (1.23-2.23) ng/ml for women without endometriosis | Null association between BPA exposure and endometriosis (aOR: 0.96, 95% CI: 0.79, 1.19 for operative cohort; aOR: 1.68, 95% CI: 0.96, 2.92 for population cohort) | Collection of urine samples across the menstrual cycle, not originally powered to examine BPA and endometriosis, short interval between measurement of BPA and diagnosis of endometriosis, exploratory analysis |
| Cobellis et al. 2009 | Case-control | Women undergoing laparoscopy for chronic pelvic pain | 69 (58 cases, 11 controls) | At the time of laparoscopy/ diagnosis of endometriosis | Mean \pm SD: 2.91 \pm 1.74 ng/mL serum (in a subset of 15 women) | Positive association of BPA with endometriosis. BPA was detectable in 52% of women with endometriosis. No detectable BPA in controls. | Small sample size, limited information on exposure and confounders |

| Source | Study design | Study population | Sample size | Timing of BPA measurement | BPA concentration (mean, geometric mean or median) | Outcome | Comments/limitations |
|----------------------|--------------------------------------|---|--------------------------|---|---|---|---|
| Ehrlich et al 2012a | Prospective cohort | Women undergoing IVF (Massachusetts General Hospital) | 137 (180 IVF cycles) | Preconception (day of egg retrieval and start of cycle) | Median: 1.53 ng/mL urine (specific gravity-adjusted) | Positive linear dose response association between BPA and implantation failure (aOR: 1.02, 1.60 and 2.11 for BPA quartiles 2, 3 and 4 compared to quartile 1 (p-trend = 0.06)) | Not adjusted for male BPA exposure or semen quality, BPA measured twice per treatment cycle |
| Ehrlich et al. 2012b | Prospective cohort | Women undergoing IVF (Massachusetts General Hospital) | 174 (237 IVF cycles) | Preconception (day of egg retrieval and start of cycle) | Median: 1.50ng/mL urine (specific gravity-adjusted) | Negative association of female BPA with peak estradiol: mean decrease of 40, 253 and 471 pg/ml (p-trend 0.001); mean number of retrieved oocytes, mature and normally fertilized oocytes decreased by 24% to 27% respectively for highest vs. lowest BPA quartile (p-trend = 0.002); trend in decreased blastocyst formation (p-trend = 0.08) | Not adjusted for male BPA exposure or semen quality, BPA measured twice per treatment cycle |
| Ehrlich et al. 2013 | Subset of ongoing prospective cohort | Women undergoing IVF (Massachusetts General Hospital) | 61 women (76 IVF cycles) | Preconception (day of egg retrieval and start of cycle) | Median: 2.59 ug/L for early cycle (day 3-9) and 1.97 ug/L for the retrieval day urine | Possible U-shaped association of BPA with mean Cyp19 expression: β estimate (95% CI) for quartiles 2, 3, and 4 compared to lowest quartile: -0.97 (-2.22, 0.28), -0.97 (-2.18, 0.24), and -0.38 (-1.58, 0.82) | Limited sample size, unknown if urinary BPA levels reflects BPA levels at the ovarian follicle, timing of urine sample may not reflect relevant biological window of exposure |

| Source | Study design | Study population | Sample size | Timing of BPA measurement | BPA concentration (mean, geometric mean or median) | Outcome | Comments/limitations |
|-----------------------|-----------------|--|---|--|--|--|--|
| Fujimoto et al. 2011 | Cohort | Women undergoing ICSI (University of California-San Francisco) | 58 infertile female and 37 male partners undergoing IVF | Preconception (day of egg retrieval) | Median: 2.53 ng/mL (women); 0.34 ng/mL (men) serum (unconjugated) | Null association between female BPA and oocyte maturation (aRR: 1.01, 95% CI: 0.98, 1.05). In 9 Asian women, significantly decreased oocyte maturation for a doubling of BPA (aRR: 0.91, 95% CI: 0.83, 1.00). Negative association of female BPA with fertilization (aRR: 0.45, 95% CI 0.21, 0.66) | Small sample size, single serum BPA, timing of male exposure not clear, larger than expected difference in median serum BPA in men and women |
| Galloway et al. 2010 | Cross-sectional | Pre-menopausal women (INChianti cohort, Italy) | 61 | Random day of menstrual cycle | Geometric mean: 3.25 ng/mL (3.04–3.47) urine (creatinine-adjusted) | Null association of BPA with estradiol ($\beta = -0.026$, 95% CI: -0.066, 0.014), null association with total testosterone; positive association with SHBG ($\beta = 0.029$, 95% CI: 0.004, 0.054) | Small sample size, single urine BPA estradiol measured at non-specified time during menstrual cycle |
| Kandaraki et al. 2011 | Case-control | PCOS clinic cases and gynecology controls (Greece) | 171 (71 cases PCOS; 100 controls) | At time of diagnosis of PCOS, follicular phase | Mean \pm SD: 1.05 \pm 0.56 ng/mL (PCOS) vs. 0.72 \pm 0.37 ng/mL [controls (p value<0.001)] serum | Positive association of BPA with PCOS ($r = 0.497$, $p < 0.05$) for all PCOS cases vs. controls and also after stratifying by lean and obese phenotypes | Cases and controls matched by age and BMI, serum BPA by ELISA (sub-optimal) |
| Lee SH et al. 2013 | Case-control | Girls experiencing precocious puberty | 114 (82 cases; 32 controls) | Childhood (7-10yr at regular checkup) | Mean \pm SD: peripheral-precocious puberty, 8.7 \pm 7.6 μ g/g creatinine; central-precocious puberty, 8.0 \pm 9.9 μ g/g creatinine; controls, 6.6 \pm 7.3 μ g/g creatinine urine | Null association of BPA with precocious puberty. No differences in steroid metabolism between girls with and without precocious puberty, but possible positive association between BPA levels and testosterone, estradiol and pregnenolone in all subjects. | Cases and controls matched by age, urine BPA by GC-MS, small sample size |

| Source | Study design | Study population | Sample size | Timing of BPA measurement | BPA concentration (mean, geometric mean or median) | Outcome | Comments/limitations |
|---------------------|--------------------|--|--|--|--|---|---|
| Mok-Lin et al. 2010 | Prospective cohort | Women undergoing IVF (Massachusetts General Hospital) | 84 (112 IVF cycles) | Preconception (day of egg retrieval and start of cycle) | Median: 2.53ng/mL urine (specific gravity-adjusted) | Negative association of BPA with peak estradiol and oocyte yield with 213pg/ml (p = 0.03) decrease in estradiol, and 12% (p = 0.007) decrease in number of oocytes retrieved per log unit increase in BPA | Small sample size, no adjustment for male exposure or semen quality, BPA measured twice per treatment cycle |
| Qiao et al. 2010 | Case-control | Girls with and without precocious puberty | 110 girls with precocious puberty and 100 girls without precocious puberty | At time of estradiol, ovary, and uterine measurements | Detected in 40.9% of precocious girls and 2% of controls | Positive association with volume of the uterus (r = 0.557, p < 0.05) and volume of the ovary (r = 0.469, p < 0.01) in precocious girls | Small sample size, no longitudinal data |
| Wolff et al. 2008a | Cross-sectional | 9 year old girls (inner city New York city 1996-1997) | 192 | At time of pubertal assessment in childhood | Geometric mean: 0.24 vs. 0.11 µg/g creatinine for breast stage 1 vs. 2; 0.19 vs. 0.10 µg/g creatinine for pubic hair stage 1 vs. 2 | Null association of BPA with breast development (PR: 0.96, 95% CI: 0.92, 1.01) and pubic hair growth (PR: 0.98, 95% CI: 0.89, 1.08) | Cross-sectional study |
| Wolff et al. 2008b | Prospective cohort | Mother-infant pairs | 404 | Mainly third trimester of pregnancy (25% of samples collected between 25-30 weeks, 45% between 31-35 weeks, and remainder between 36-40 weeks) | Range : 0.7-35.2 µL | Null association of BPA with birth weight, birth length, head circumference, and gestational age | One measure of BPA during third trimester |
| Wolff et al. 2010 | Prospective cohort | 6-8 year old girls (multicenter: NYC, Cincinnati, California, 2004-2007) | 1151 | Childhood (6-8yr at baseline visit) | Median : 2.0 ng/mL urine (creatinine-adjusted) | Null association of BPA with early onset of pubertal development (p-trend = 0.53) | One measure of BPA at baseline –1 year before reassessment of puberty development |

aOR=adjusted odds ratio; aRR=adjusted relative risk; CI=confidence interval; ELISA=enzyme-linked immunoabsorbant assay; GC-MS=gas chromatography-mass spectrometry; ICSI= intracytoplasmic sperm injection; IVF=*in vitro* fertilization; PCOS=polycystic ovarian syndrome

Table S3. BPA and uterine outcomes in experimental studies.

| Source | Animal | Strain | Exposure route | Time of exposure | Doses | Age at collection | Outcome |
|-------------------------|-------------------|----------------------|---|-----------------------------------|--------------------|----------------------|---|
| Aghajanova et al. 2011 | Human | NA | <i>In vitro</i> : Endometrial stromal fibroblasts | 48 hours | 5-100µmol/L | NA | Decreased steroidogenic gene expression |
| Aldad et al. 2011 | Non-human primate | African green monkey | Alzet minipump | Postnatal exposure: 28 days | 50µg/kg | Adult | Decreased progesterone receptor expression |
| Aldad et al. 2011 | Non-human primate | African green monkey | <i>In vitro</i> : Ishikawa cells | 24 hours | 1µM | Adult | Decreased progesterone receptor expression |
| An et al. 2013 | Rat | Sprague-Dawley | Subcutaneous injection | Neonatal exposure: PND17-PND19 | 10, 100, 500mg/kg | PND20 | Decreased contractile activity |
| Benachour and Aris 2009 | Human | NA | <i>In vitro</i> : Cytotrophoblasts | 24 hours | 0.0002- 200µg/mL | After 24h of culture | Increased apoptosis and necrosis, induced AK activity and <i>Tnfa</i> gene and protein expression |
| Berger et al. 2008 | Mouse | CF-1 | Subcutaneous injection | Gestational exposure: GD1-GD4 | 0.01-300mg/kg | GD6 | Decreased number of implantation sites, decreased progesterone |
| Berger et al. 2008 | Mouse | CF-1 | Subcutaneous injection | Gestational exposure: GD0,1, or 2 | 200 and 300mg/kg | GD6 | Decreased number of implantation sites, decreased progesterone |
| Berger et al. 2010 | Mouse | CF-1 | Subcutaneous injection | Gestational exposure: GD1-GD4 | 100, 200, 300mg/kg | GD6 | Increased luminal epithelial cell height, altered estrogen receptor and progesterone receptor gene expression |
| Bosquiazzo et al. 2010 | Rat | Wistar | Subcutaneous injection | Neonatal exposure: PND1,3,5,7 | 0.05 and 20mg/kg | PND94 | Decreased endometrial proliferation, decreased <i>Vegf</i> expression |
| Bredhult et al. 2009 | Human | | <i>In vitro</i> : Endometrial epithelial cells | 24 hours | 50µM | After 24h of culture | Decreased endometrial epithelial cell proliferation |
| Bromer et al. 2010 | Mouse | CD-1 | Intraperitoneal injection | Gestational exposure: GD9-GD16 | 5mg/kg | 2 or 6 weeks old | Decreased methylation of <i>Hoxa10</i> promoter |

| Source | Animal | Strain | Exposure route | Time of exposure | Doses | Age at collection | Outcome |
|-------------------------------|--------|---------------|---|--|---|---|--|
| Hiyama et al. 2011 | mouse | ICR | Subcutaneous injection | Gestational exposure: GD12-GD16 | 100-1000mg/kg | F1 and F2: 8 weeks | Increased uterine luminal space. decreased uterine epithelium, decreased methylation of <i>Hoxa10</i> intron |
| Mendoza-Rodriquez et al. 2011 | Rat | Wistar | Drinking water | Gestational and neonatal exposure: GD6-PND21 | 10mg/L (1.2mg/kg) | 7 weeks old | Increased uterine stroma and epithelium thickness, decreased uterine epithelial apoptosis |
| Morice et al. 2011 | Human | NA | <i>In vitro</i> : JEG-3 trophoblast cells | 24-72h | 10 ⁻⁵ M to 10 ⁻¹⁰ M | 4-8 week placental cells | Decreased cell proliferation. Increased apoptosis |
| Newbold et al. 2009 | Mouse | CD-1 | Subcutaneous injection | Gestational exposure : GD9-16 | 0, 0.1, 1, 10, 100, 1000µg/kg | 18months old | Increased uterine abnormalities |
| Salian et al. 2009a | Rat | Holtzman | Subcutaneous injection | Neonatal exposure (males only): PND1-PND5 | 100-1600µg/kg | PND15, 30, 45, 90 | Increased fetal resorption, increased pre-implantation loss, decreased litter size |
| Salian et al. 2009b | Rat | Holtzman | Oral gavage | Gestational and neonatal exposure (males only): GD12-PND21 | 1.2 and 2.4µg/kg | GD20 or PND125 | Increased fetal resorption, decreased litter size, increased hormone imbalances |
| Signorile et al. 2010 | Mouse | Balb-c | Subcutaneous injection | Gestational exposure : GD1-PND7 | 100 and 1000µg/kg | 3 months old | Increased endometriosis-like structures |
| Susiarjo et al. 2013 | Mouse | C57BL/6 Cast7 | Dietary exposure | Gestational exposure: Prebreed to GD9.5 | 10µg/kg and 10mg/kg | F1: GD9.5 | Disrupted imprinted gene expression in embryos and placenta |
| Tan et al. 2013 | Mouse | ICR | Oral gavage | Gestational exposure : GD13-GD16 | 2, 20, 200mg/kg | GD17 | Activated protein kinase C signaling |
| Tiwari and Vanage 2013 | Rat | Holtzman | Oral gavage | Postnatal exposure (males only): 6 days | 5 and 10µg/kg | GD15 (untreated female mated to treated male) | Decreased implantation sites, increased resorption sites |

| Source | Animal | Strain | Exposure route | Time of exposure | Doses | Age at collection | Outcome |
|--------------------------|---------|---------------|------------------------|---------------------------------------|---------------------------------|-------------------|--|
| Varayoud et al. 2008 | Rat | Wistar | Subcutaneous injection | Neonatal exposure: PND 1, 3, 5, and 7 | 0.5 and 20mg/kg | PND8 or PND94 | Decreased steroid hormone responsiveness of uterine stroma, decreased <i>Hoxa10</i> and <i>Hoxa11</i> expression |
| Varayoud et al. 2011 | Rat | Wistar | Subcutaneous injection | Neonatal exposure: PND1, 3, 5, and 7 | 0.05 and 20mg/kg | F1: GD5 or GD18 | Decreased implantation sites, decreased implantation-regulating gene expression |
| Xiao et al. 2011 | Mouse | C57BL/6 | Subcutaneous injection | Gestational exposure: GD0.5-GD3.5 | 0, 0.025, 0.5, 10, 40, 100mg/kg | GD4.5 or GD5.5 | Ablated implantation, decreased embryo transport |
| Yigit and Daglioglu 2010 | Chicken | White Leghorn | In ovo injection | Incubation day 4 | 67 and 134µg/g | 21 weeks old | Decreased hatching proportion, uterine tubular glandular density, and thickness of tunica mucosa |

AK=adenylate kinase; GD=gestation day; HOXA=homeobox A; GD=gestation day; PND=postnatal day; Tnfa=tumor necrosis factor alpha; vegf=vascular endothelial factor

Table S4. BPA and human pregnancy and birth outcomes.

| Source | Study design | Study population | Sample Size | Timing of BPA measurement | BPA concentration (mean, geometric mean or median) | Outcome | Comments/limitations |
|-----------------------|---|--|------------------------------|---|---|--|---|
| Cantowine et al. 2010 | Nested case-control in a prospective cohort | Pregnant women Mexico city (ELEMENT cohort) | 60 (12(20%) preterm births) | Third trimester archived spot urine samples | Geometric mean: 1.45ng/mL for all women; 1.94ng/mL for women delivering preterm. Urine (SG- adjusted) | Borderline positive BPA association with preterm birth, (OR 1.91, 95% CI: 0.93, 3.91) | Pilot study, small sample size |
| Chou et al. 2011 | Cross-sectional | Taiwanese mothers and infants | 97 | At delivery | Geometric mean: 2.5ng/mL (maternal serum); 0.5ng/mL (neonatal cord blood) | Positive association of BPA with low birth weight (OR 2.42, 95% CI: 1.72, 3.36); small for gestational age (OR 2.01, 95% CI: 1.39, 3.01); high leptin (OR 1.67, 95% CI: 1.12, 2.25); and low adiponectin (OR 1.25, 95% CI: 1.52, 3.97) | Small sample size, cross sectional design |
| Fenichel et al. 2012 | Matched case-control | Boys with cryptorchidism (France) | 152 (46 cases; 106 controls) | Cord blood at birth | Median: 0.86ng/mL in controls); 0.92ng/mL in cases serum (unconjugated) | Null association of BPA with cryptorchidism. However, significant positive correlation with testosterone and inhibin B levels | Exposure assessment of maternal BPA during pregnancy is important given the short half -life of BPA |
| Lee BE et al. 2013 | Multi-center birth cohort | Korean mothers and children | 757 | Third trimester | Geometric mean: 1.29µg/L (1.87µg/g creatinine) during late pregnancy | Positive association between BPA levels and birth weight; second tertile of maternal BPA exposure exhibited an increase in birth weight relative to the first tertile (p = 0.04) | Urine levels of BPA may not reflect circulating levels, used spot urines. BPA values normalized to creatinine only |
| Miao et al. 2011a | Occupational cohort retrospective | Children of occupationally exposed Chinese parents | 587 | Exposure history and personal air sampling, job/exposure matrix; current urine in a subgroup, but not for index pregnancy | Geometric mean: Exposed mothers (direct exposure): 15.98µg/g Cr (N=50). Spouses of exposed men (indirect): 2.22µg/g Cr (N=93). Unexposed mothers: 0.56µg/g Cr (N=444) urine (cr-adjusted) | Negative association of BPA with birth weight ($\beta = -168g$, p = 0.02) for directly exposed fetus (maternal exposure); ($\beta = -91g$, p = 0.10) for indirectly exposed fetus (father exposed during pregnancy) | 30-50% of women had their index pregnancy over 15 years prior to enrollment to the study, exposure was partly estimated using exposure history of occupational exposure, self-report of baby's birth weight. possible recall bias exists due elapsed time |

| Source | Study design | Study population | Sample Size | Timing of BPA measurement | BPA concentration (mean, geometric mean or median) | Outcome | Comments/limitations |
|-------------------------|---|---|------------------------------|--|---|--|--|
| Miao et al. 2011b | Occupational cohort study retrospective | Children of occupationally exposed parents (age 0-17 years) | 153 (106 controls, 46 cases) | Personal air sampling at time of index pregnancy, current urine for different categories of exposure as defined using occupational history and job/exposure matrix | Geometric mean: Exposed mothers (direct exposure): 16.0 µg/g Cr (N=18). Spouses of exposed men (indirect): 2.2µg/g Cr (N=38). Unexposed mothers: 0.6µg/g Cr(N=97) Urine (cr-adjusted) | Positive linear dose response association of BPA with shortened AGD in boys by level of exposure, p-trend = 0.008; in boys of exposed mothers, decrease in AGD of 8.11mm (p = 0.003) and 2.87mm (p = 0.15) in boys of exposed fathers during index pregnancy | Wide age range of children at time of AGD measurement. Almost 20% of boys were older than 10 years. Uncertain generalizability to the environmentally exposed population |
| Padmanabhan et al. 2008 | Cross-sectional | Southeastern Michigan mothers | 40 | At delivery | Mean (SEM): 5.9 (0.94) ng/mL serum (unconjugated) | Null association of BPA with birth weight and gestational length. Mothers with maternal BPA concentrations less than or equal to 5ng/ml had babies with similar birth weight to mothers with maternal BPA concentrations above 5ng/mL | Small sample size, limited information on exposure by birthweight (cut-off of 5ng/mL used in analyses), single spot serum at delivery |
| Philippat et al. 2012 | Nested case-control | Mother-infant male pairs (France) | 191 | 6-30 weeks gestation | Median: 3.1ng/mL (in mother) urine | Suggestive inverted U-shape association between BPA and birth weight in tertile analysis 169g (95% CI: 14, 324); 85g (-62, 233) for tertile 2 and 3, respectively. Increase in head circumference by 0.3cm (95% CI: 0.0, 0.7) | Single spot urine sample at one time point during pregnancy |
| Snijder et al. 2013 | Prospective cohort study | Pregnant Dutch women | 219 | Early, mid, and late pregnancy | Geometric mean (SEM): 3.2 (2.3) µg/g creatinine | Negative association of BPA with fetal growth and head circumference. Among 80 women with three BPA measurements, women with BPA levels above 4.22µg/g creatinine had lower fetal growth rates and fetuses with smaller head circumference than women with BPA levels less than 1.54µg/g creatinine. | Small sample size, difficult to obtain solid estimate of first trimester fetal growth |

| Source | Study design | Study population | Sample Size | Timing of BPA measurement | BPA concentration (mean, geometric mean or median) | Outcome | Comments/limitations |
|--------------------|---------------------|-------------------------|--------------------|--|---|--|---|
| Wolff et al. 2008b | Prospective cohort | Mother-infant pairs | 404 | Mainly third trimester of pregnancy (25% of samples collected between 25-30 weeks, 45% between 31-35 weeks, and remainder between 36-40 weeks) | Range : 0.7-35.2µL | Null association of BPA with birth weight, birth length, head circumference, and gestational age | One measure of BPA during third trimester |

AGD=anogenital distance; CI=confidence interval; Cr=creatinine; OR=odds ratio; SEM=standard error of the mean; SG=specific gravity

Table S5. BPA and pregnancy outcomes in experimental studies.

| Source | Animal | Strain | Exposure route | Time of exposure | Doses | Age at collection | Outcome |
|------------------------|--------|----------------|------------------------|---|-----------------------------------|--------------------------------|---|
| Cabaton et al. 2011 | Mouse | CD-1 | Alzet pump | Gestational exposure: GD8-PND16 | 25ng, 250ng, 25µg/kg | 2-8months old | Decreased number of pregnancies, decreased number of pups |
| Howdeshell et al. 2008 | Rat | Long-Evans | Oral gavage | Gestational exposure: GD7-PND18 | 2, 20, 200µg/kg | PND150 | No adverse effects on pregnancy outcomes |
| Kobayashi et al. 2010 | Mouse | C57BL/6 | Dietary exposure | Gestational, neonatal, and postnatal exposure: F1: GD6-PND22; postnatal until sacrifice | 0.05, 0.5, 5.0mg/kg | F1: 13 weeks | No adverse effects on pregnancy outcomes |
| Kobayashi et al. 2010 | Mouse | C57BL/6 | Dietary exposure | Gestational, neonatal, and postnatal exposure: F2: GD6-PND22; postnatal until sacrifice | 0.05, 0.5, 5.0mg/kg | F2:15 weeks | No adverse effects on pregnancy outcomes |
| Kobayashi et al. 2012 | Rat | Sprague-Dawley | Dietary exposure | Gestational and neonatal exposure: GD6-PND21 | 0.05, 0.5, 5.0mg/kg | 5weeks; 3 months | No adverse effects on pregnancy outcomes |
| Nah et al. 2011 | Mouse | ICR | Subcutaneous injection | Neonatal exposure: PND8 | 0.1, 1, 10, 100mg/kg | PND20-PND29; PND25, 30, 70 | Decreased pup weight |
| Nanjappa et al. 2012 | Rat | Long-Evans | Oral gavage | Gestational exposure: GD12-PND21 | 2.5 and 25µg/kg | PND90 | No adverse effects on pregnancy outcomes |
| Ryan BC et al. 2010 | Rat | Long-Evans | Oral gavage | Gestational and neonatal exposure: GD7-PND18 | 2, 20, 200µg/kg | | No adverse effects on pregnancy outcomes |
| Salian et al. 2009a | Rat | Holtzman | Subcutaneous injection | Neonatal exposure (males only): PND1-5 | 100-1600µg/kg | PND15, 30, 45, 90 | Decreased number of pups |
| Salian et al. 2009b | Rat | Holtzman | Oral gavage | Gestational exposure (males only): GD12-PND21 | 1.2 and 2.4µg/kg | Males: PND125 Females: GD20 | Decreased number of pups |
| Tan et al. 2013 | Mouse | ICR | Oral gavage | Gestational exposure: GD13-GD16 | 2, 20, 200mg/kg | GD17 | Placenta gene changes that could cause pre-term birth |
| Thuillier et al. 2009 | Rat | Sprague-Dawley | Oral gavage | Gestational exposure: GD14-PND0 | 0.1 to 200mg/kg | PND 3, 21, 60 | No adverse effects on pregnancy outcomes |
| Tyl et al. 2008 | Mouse | CD-1 | Dietary exposure | Gestational exposure: F0 8 weeks pre-breed, GD1-GD14 | 0.003, 0.03, 0.3, 5, 50, 600mg/kg | PND1/birth | Increased pup weight |

| Source | Animal | Strain | Exposure route | Time of exposure | Doses | Age at collection | Outcome |
|--------------------------|---------|---------------|------------------|--|-----------------------------------|-------------------|--|
| Tyl et al. 2008 | Mouse | CD-1 | Dietary exposure | Postnatal exposure: F1:8 weeks pre-breed | 0.003, 0.03, 0.3, 5, 50, 600mg/kg | PND1/birth | Increased pup weight |
| Xi et al. 2011 | Mouse | CD-1 | Oral gavage | Postnatal exposure: F0: GD1-PND20 | 12, 25, 50mg/kg | PND50 | No adverse effects on pregnancy outcomes |
| Xi et al. 2011 | Mouse | CD-1 | Oral gavage | Postnatal exposure: F1: PND21-PND49 | 12, 25, 50mg/kg | PND50 | No adverse effects on pregnancy outcomes |
| Xi et al. 2011 | Mouse | CD-1 | Oral gavage | Postnatal exposure: F1: PND21-49 | 12, 25, 50mg/kg | PND50 | No adverse effects on pregnancy outcomes |
| Yigit and Daglioglu 2010 | Chicken | White Leghorn | In ovo injection | Incubation day 4 | 67 and 134µg/g | 21 weeks old | Decreased hatching |

F0=parental generation; F1=first filial generation; GD=gestation day; PND=postnatal day

Table S6. BPA and male human reproductive outcomes.

| Source | Study design | Study population | Sample Size | Timing of BPA measurement | BPA concentration (mean, geometric mean or median) | Outcome | Comments/limitations |
|----------------------|--------------------------|--|-------------|---|--|---|--|
| Galloway et al. 2010 | Cross-sectional | Italian adults between 20-74 years of age (INChianti) | 715 | Adulthood, same day as testosterone measure | Geometric mean: 4.02ng/mL (3.76–4.31) urine (creatinine-adjusted) | Positive association of BPA with total testosterone ($\beta = 0.05$, 95% CI: 0.02, 0.08), no association with sex hormone binding globulin and free testosterone | Relatively high BPA concentration for general population, cross-sectional study design, spot urine sample |
| Li DK et al. 2010 | Cross-sectional | Occupationally exposed men from 4 regions of China | 427 | Pre and post shift | Median : 53.7 μ g/g creatinine (occupationally exposed) and 1.2 μ g/g Cr (unexposed) urine (creatinine-adjusted) | Positive association of BPA with sexual dysfunction, decreased sexual desire ($\beta = 0.016$, $p < 0.001$), erectile dysfunction ($\beta = 0.022$, $p < 0.001$), orgasmic function ($\beta = -0.017$, $p < 0.001$), and overall satisfaction with sex life ($\beta = -0.010$, $p = 0.003$) | Self-reported sexual dysfunction, low participation rate, possible current co-exposures |
| Li DK et al. 2011 | Prospective cohort study | Occupationally exposed Chinese men | 218 | Pre and post shift | Median: 38.7ng/mL (occupationally exposed) and 1.4ng/mL (unexposed) urine (creatinine-adjusted) | Negative linear association of BPA with sperm concentration ($\beta = 15.6$, $p < 0.001$); sperm count ($\beta = -42.1$, $p = 0.004$) and increased odds of decreased sperm motility (OR: 2.3, 95% CI: 1.0, 5.1). Associations stronger after excluding occupationally exposed men. | Only two semen samples collected at 1-3 week intervals, small sample size for sub-analysis on men not occupationally exposed to BPA (N=88), uncertain generalizability to men exposed to environmentally relevant BPA concentrations |
| Meeker et al. 2010a | Cross-sectional | Male partners of couples seeking treatment for subfertility (Massachusetts General Hospital) | 190 | Same day as semen sample collection (additional urine samples for a subgroup collected weeks to months prior to semen sample) | Median: 1.3ng/mL urine (specific gravity-adjusted) | Negative association of BPA with sperm concentration: -23% (95% CI: -40%, -0.3%), morphology: -13% (95% CI: -26%, -0.1%), suggestive decrease in sperm motility: -7.5% (95% CI: -17%, 1.5%), and increase in sperm DNA damage: 10% (95% CI: 0.03%, 19%) | Associations only observed when semen parameters were modeled on a continuous scale, but not when modeled as binary outcome, uncertain generalizability of results to men from general population |

| Source | Study design | Study population | Sample Size | Timing of BPA measurement | BPA concentration (mean, geometric mean or median) | Outcome | Comments/limitations |
|----------------------|-----------------|--|---|--|--|--|---|
| Meeker et al. 2010b | Cross-sectional | Male partners of couples seeking treatment for subfertility (Massachusetts General Hospital) | 167 | Same day as blood sample for hormone measurements. Repeat samples in 75 men up to 2.5 months later | Median: 1.3ng/mL urine (specific gravity-adjusted) | Negative association of BPA with estradiol:testosterone ratio ($\beta = 0.86$, $p = 0.01$) and free androgen index ($\beta = 0.89$, $p = 0.02$), and positively associated with FSH ($\beta = 1.18$, $p = 0.01$) and FSH:inhibin B ratio ($\beta = 1.28$, $p = 0.05$) | Cross sectional study design, negative association with estradiol:testosterone ratio was consistent when modeling repeat urine BPA concentrations, but only a limited number of repeat samples were available, generalizability to men of general population is uncertain |
| Mendiola et al. 2010 | Cross-sectional | Fertile male partners of pregnant women (Multicenter: Study for Future Families) | 302 men (hormones) 317 men (semen quality) | Same day as hormone profile and semen collection | Median: 1.7 ng/mL urine (unadjusted) creatinine-adjusted | Positive association of BPA with sex hormone binding globulin ($\beta = 0.07$, 95% CI: 0.007, 0.13). Negative association with free androgen index ($\beta = -0.01$, 95% CI: -0.09, -0.004) and free androgen index: luteinizing hormone ratio ($\beta = -0.11$, 95% CI: -0.18, -0.03). Null associations with semen quality parameters. | Cross sectional study design |

CI=confidence interval; Cr= creatinine; FSH=follicle-stimulating hormone; OR=odds ratio

Table S7. BPA and male reproductive outcomes in experimental studies.

| Source | Animal | Strain | Exposure route | Time of exposure | Doses | Age at collection | Outcome |
|---------------------------------------|--------|----------------|------------------------|--|------------------------------|---|---|
| Arase et al. 2011 | Mouse | C57BL/6 | Oral gavage | Gestational exposure: GD13-GD16 | 20µg/kg | GD17 to PND1 | Increased estradiol levels, increased steroidogenic enzyme expression in urogenital sinus |
| Anjum et al. 2013 | Mouse | Swiss albino | Oral exposure | Postnatal exposure: adult | 10mg/kg body weight | Adult, exact age unknown, after 14 days of dosing | Increased oxidative stress in testes |
| Castro et al. 2013 | Rat | Wistar | Subcutaneous injection | Postnatal exposure: adult (4 days) | 25, 50, 300, and 600µg/kg | Adult (exact age not reported, 30 min after last injection) | Decreased testosterone, increased estradiol |
| D'Cruz et al. 2012a | Rat | Wistar | Oral gavage | Postnatal exposure: 90-135 days old (45 days) | 0.005, 0.5, 50, 500µg/kg | 136 days old | Decreased expression of glucose transporters, increased reactive oxygen species production |
| D'Cruz et al. 2012b | Rat | Wistar | Oral gavage | Postnatal exposure: 90-135 days old (45 days) | 0.005, 0.5, 50, 500µg/kg | 136 days old | Decreased insulin signaling, decreased glucose transport, decreased steroidogenic enzymes. decreased testosterone |
| De Flora et al. 2011 | Rat | Sprague-Dawley | Drinking water | Postnatal exposure: adult (10 days) | 200mg/kg | Adult (exact age not reported, 24h after last exposure day) | Increased sperm DNA fragmentation, increased DNA adducts in prostate, increased clusterin expression |
| Dobrzynska and Radzikowska 2013 | Mouse | Pzh:SFIS | Drinking water | Postnatal exposure: 8-10 weeks (14 days) | 5, 10, 20, 40mg/kg | 10 weeks old | Decreased sperm count and motility, increased abnormal morphology of sperm, induced sperm DNA strand breaks |
| El-Beshbishy et al. 2012 | Rat | Albino | Oral exposure | Postnatal exposure: adult (14 days) | 10mg/kg | Adults (exact age not reported, after last exposure day) | Decreased testes weight and protein content, decreased antioxidant enzymes, decreased glutathione content, increased lipid peroxidation, decreased testosterone |
| Fang et al 2013 | Mouse | Kunming | Oral gavage | Postnatal exposure: 4-5 weeks | 0.5mg/kg body weight | 3 weeks after last dose | Increased oxidative stress, decreased testes weight, decreased testosterone |

| Source | Animal | Strain | Exposure route | Time of exposure | Doses | Age at collection | Outcome |
|------------------------|--------|----------------|-----------------------|---|-----------------------|-------------------------|--|
| Horstman et al. 2012 | Rat | Sprague-Dawley | Subcutaneous exposure | Gestational exposure: GD11-GD20 | 0.02, 0.5, 400mg/kg | F1: GD16, 18, or 20 | Decreased <i>Star</i> expression and protein levels |
| Howdeshell et al. 2008 | Rat | Long-Evans | Oral gavage | Gestational and postnatal exposure: GD7-PND18 | 2, 20, and 200µg/kg | PND150 | No change in reproductive organ weight, no effect on AGD |
| Jin et al. 2013 | Rat | Sprague-Dawley | Oral gavage | Postnatal exposure: 12-14 weeks (14 weeks) | 2 µg/kg | 14 weeks old | Decreased hormone production, decreased sperm and germ cell count, no change in testis weight, increased apoptosis |
| Kobayashi et al. 2010 | Mouse | C57BL/6 | Dietary exposure | Gestational, neonatal, and postnatal exposure: GD6-PND22; postnatal until sacrifice | 0.05, 0.5, 5.0mg/kg | 13 or 15 weeks old | Reduced sperm motility, no change in sperm count, AGD, or reproductive organ weight |
| Kobayashi et al. 2012 | Rat | Sprague-Dawley | Dietary exposure | Gestational and neonatal exposure: GD6-PND21 | 0.017, 0.17, 1.7mg/kg | 5 weeks or 3 months old | No change in hormones, sperm count/motility, AGD, testis, or prostate weight |
| LaRocca et al. 2011 | Mouse | C57BL/6 | Oral gavage | Gestational exposure: GD10-GD16 | 50 and 1000µg/kg | PND56 | No effect on spermatogenesis, Sertoli cell gene expression, serum testosterone levels, or AGD |
| Li Y et al. 2009 | Mouse | Kunming | Oral gavage | Postnatal exposure: PND31-PND44 | 160, 480, 960mg/kg/d | PND 45, 60, 90 | Increased germ cell apoptosis, Leydig cell apoptosis, decreased spermatogenesis, increased FasL signaling |
| Liu et al. 2013 | Rat | Wistar | Oral gavage | Postnatal exposure: 9-18 weeks old (60 days) | 2, 20, 200µg/kg | 18 weeks old | Decreased sperm counts, inhibited spermiation, persistent meiotic DNA strand breaks, increased germ cell apoptosis |
| Minamiyama et al. 2010 | Rat | Wistar | Drinking water | Postnatal exposure: 8-16 weeks old (56 days) | 1.0 or 10mg/L | 16 weeks old | No change in sperm count, reduced sperm motility, increased production of ROS in sperm |
| Minamiyama et al. 2010 | Rat | Wistar | Drinking water | Postnatal exposure: 12 weeks old (7 days) | 1.0mg/L | 12 weeks old | No change in sperm count, reduced sperm motility, increased production of ROS in sperm |

| Source | Animal | Strain | Exposure route | Time of exposure | Doses | Age at collection | Outcome |
|-------------------------|--------|----------------|--------------------------------|---|---|---|---|
| Nakamura et al. 2010 | Rat | Wistar/st | Subcutaneous injection | Postnatal exposure: 4-9 weeks old (4 days a week for 6 weeks) | 20, 100, 200mg/kg (11.4, 57.1, 114.2 mg/kg/day) | 9 weeks old | Decreased serum and intratesticular testosterone, decreased steroidogenic enzyme expression, decreased <i>Esr1</i> expression, decreased Leydig cell number, decreased LH |
| Nanjappa et al. 2012 | Rat | Long-Evans | Oral gavage | Gestational and neonatal exposure: GD12-PND21 | 2.5 and 25µg/kg | PND 21,35, 90 | Increased Leydig cell number, decreased Leydig cell testosterone production, increased LHR, ESR1, AR |
| N'Tumba-Byn et al. 2012 | Human | NA | <i>In vitro</i> : Fetal testes | 3 days | 10pM-10µM | 6.5-10.5 gestational weeks | Reduced testosterone and INSL3 mRNA levels |
| N'Tumba-Byn et al. 2012 | Rat | Wistar | <i>In vitro</i> : Fetal testes | 3 days | 10pM-10µM | 14.5 DPC | Reduced testosterone in rodent testes |
| N'Tumba-Byn et al. 2012 | Mouse | C57BL/6 | <i>In vitro</i> : Fetal testes | 3 days | 10pM-10µM | 12.5 DPC | Reduced testosterone in rodent testes |
| Okada and Kai 2008 | Mouse | ICR | Silastic capsule | Gestational and neonatal exposure: Pre-breed through PND28 | 1.2 and 60µg/day | PND 28 | Reduced mature spermatids number, no change in testosterone |
| Prins et al. 2011 | Rat | Sprague-Dawley | Subcutaneous injection | Neonatal exposure: PND1, 3, and 5 | 10µg/kg | 28 weeks old | Increased prostate intraepithelial neoplasia incidence |
| Prins et al. 2011 | Rat | Sprague-Dawley | Oral exposure | Neonatal exposure: PND1, 3, and 5 | 10µg/kg | 28 weeks old | Increased prostate intraepithelial neoplasia incidence |
| Qiu et al. 2013 | Rat | Sprague-Dawley | Oral gavage | Postnatal exposure: 9-16 weeks old (56 days) | 0.0005, 0.5, 5mg/kg | 16 weeks old | Altered steroidogenic enzyme expression, decreased sperm count |
| Rashid et al. 2013 | Mouse | Swiss albino | Oral exposure | Postnatal exposure: adult | 10 mg/kg body weight | Adult, exact age unknown, after 14 days of dosing | Increased oxidative stress |
| Salian et al. 2009a | Rat | Holtzman | Subcutaneous injection | Neonatal exposure: PND1-PND5 | 100-1600µg/kg | PND15, 30, 45, 90, 125 | Decreased sperm count, altered hormone production |
| Salian et al. 2009b | Rat | Holtzman | Oral gavage | Gestational and neonatal exposure: GD12-PND21 | 1.2 and 2.4µg/kg | PND125 | Decreased steroid receptors in F1, F2, F3 |
| Sánchez et al. 2013 | Rat | Wistar | Subcutaneous injection | Postnatal exposure: adult (4 days) | 25 and 300µg/kg | 30 min after last treatment | Decreased DHT levels, no effect on testosterone levels, decreased expression of <i>5αR1</i> and <i>5αR2</i> |

| Source | Animal | Strain | Exposure route | Time of exposure | Doses | Age at collection | Outcome |
|------------------------|--------|----------------|------------------------|---|-----------------------------------|---|--|
| Tainaka et al. 2012 | Mouse | ICR | Subcutaneous injection | Gestational exposure: GD7 and GD14 | 5 and 50mg/kg | F1: 6 weeks old | Decreased sperm count, gene expression mediating spermatozoa, altered Sertoli cell number and morphology, decreased genes mediating Sertoli cell function and androgen signaling |
| Tang et al. 2012 | Rat | Sprague-Dawley | Subcutaneous injection | Neonatal exposure: PND1, 3, and 5 | 10µg/kg | PND10, 90, 200 | Altered methylation and expression of genes and transcriptional proteins in prostate |
| Thuillier et al. 2009 | Rat | Sprague-Dawley | Oral gavage | Gestational exposure: GD14-PND0 | 0.1-200mg/kg | PND 3, 21, 60 | Transient alterations in the MAPK signaling pathway |
| Tiwari and Vanage 2013 | Rat | Holtzman | Oral gavage | Postnatal exposure: Adults (6 days) | 5 and 10µg/kg | End of mating cycle (treated males; 1 to 8 weeks) | Impaired mid-spermatids and spermatocytes, decreased sperm production and motility, increased sperm DNA damage |
| Tyl et al. 2008 | Mouse | CD-1 | Dietary exposure | Gestational exposure: F0: 8 weeks pre-breed, GD1-GD14 | 0.003, 0.03, 0.3, 5, 50, 600mg/kg | PND1/birth | Decreased absolute AGD and delayed preputial separation, no effect on sperm, organ weight, or reproductive organ structure |
| Tyl et al. 2008 | Mouse | CD-1 | Dietary exposure | Postnatal exposure: F1: 8 weeks pre-breed | 0.003, 0.03, 0.3, 5, 50, 600mg/kg | PND1/birth | Decreased absolute AGD and delayed preputial separation, no effect on sperm, organ weight, or reproductive organ structure |
| Wang Q et al. 2010 | Mouse | CD-1 | Oral gavage | Postnatal exposure: PND35-PND49 | 160 and 480mg/kg | PND50 | Increase germ cell apoptosis, increased FasL signaling pathway, increased mitochondrial apoptotic signaling pathway |
| Wu et al. 2013 | Rat | Sprague-Dawley | Oral gavage | Postnatal exposure: 8-10 weeks old (10 days) | 200mg/kg | 10 weeks old (24h after treatment) | Induced DNA damage, induced oxidative stress |
| Wu et al. 2011 | Rat | Sprague-Dawley | Intragastric injection | Postnatal exposure: Adult (4 weeks) | 10, 30, 90µg/kg | 12 weeks old | Decreased testosterone |

| Source | Animal | Strain | Exposure route | Time of exposure | Doses | Age at collection | Outcome |
|----------------|--------|--------|----------------|--|-----------------|-------------------|---|
| Xi et al. 2011 | Mouse | CD-1 | Oral gavage | Gestational and neonatal exposure: F0: GD1-PND20 | 12, 25, 50mg/kg | PND50 | Decreased steroidogenic enzyme expression, decreased testosterone |
| Xi et al. 2011 | Mouse | CD-1 | Oral gavage | Postnatal exposure: F1: PND21-PND49 | 12, 25, 50mg/kg | PND50 | Decreased steroidogenic enzyme expression, decreased testosterone |
| Xi et al. 2011 | Mouse | CD-1 | Oral gavage | Postnatal exposure: F1: PND21-PND49 | 12, 25, 50mg/kg | PND50 | Decreased steroidogenic enzyme expression, decreased testosterone |

AGD=anogenital distance;AR=androgen receptor; DPC=days post coitum; F0=parental generation; F1=first filial generation; F2=second filial generation; F3=third filial generation; GD=gestation day; Esr1=estrogen receptor 1;Fasl=Fas ligand; INSL=insulin like factor; LH=luteinizing hormone; MAPK=mitogen activated protein kinase; PND=postnatal day; Star=steroidogenic acute regulatory protein

Table S8. BPA and sexual function outcomes in experimental studies.

| Source | Animal | Strain | Exposure route | Time of exposure | Doses | Age at collection | Outcome |
|-------------------------|--------|----------------|------------------------|---|---------------------------------|--------------------------------|--|
| Adeyale et al. 2009 | Rat | Long-Evans | Subcutaneous injection | Neonatal exposure: PND0-PND3 | 50µg/kg and 50mg/kg | PND148 | Accelerated vaginal opening |
| DeCatanzaro et al. 2013 | Mouse | CF-1 | Dietary exposure | Postnatal exposure: GD10-PND9 | 0.175, 1.75, 17.5µg | PND60 or PND90 | Increased latency to insemination, decreased intromissions with females, decreased ejaculations |
| DeCatanzaro et al. 2013 | Mouse | CF-1 | Dietary exposure | Postnatal exposure: GD10-PND9 | 17.5, 175, 1750µg | PND85-PND105 | Increased latency to insemination, decreased intromissions with females, decreased ejaculations |
| Fernandez et al. 2009 | Rat | Sprague-Dawley | Subcutaneous injection | Gestational exposure: PND1-10 | 5µg/50µL, 50µg/50µL, 500µg/50µL | PND12; adults | Accelerated puberty onset and estrous cyclicity, decreased gonadotropin releasing hormone and luteinizing hormone function |
| Nah et al. 2011 | Mouse | ICR | Subcutaneous injection | Neonatal exposure: PND8 | 0.1, 1, 10, 100mg/kg | PND20-PND29; PND25, 30, 70 | Accelerated vaginal onset, decreased estrous cyclicity |
| Ryan et al. 2010 | Rat | Long-Evans | Oral gavage | Gestational and neonatal exposure: GD7-PND18 | 2, 20, 200µg/kg | NA | No adverse sexual function effects |
| Salian et al. 2009a | Rat | Holtzman | Subcutaneous injection | Neonatal exposure (males only): PND1-5 | 100-1600µg/kg | PND15, 30, 45, 90 | Increased time taken for copulation, decreased copulation index |
| Salian et al. 2009b | Rat | Holtzman | Oral gavage | Gestational exposure (males only): GD12-PND21 | 1.2 and 2.4µg/kg | males: PND125 females: GD20 | Increased time taken for copulation in F1, F2, F3 |

| Source | Animal | Strain | Exposure route | Time of exposure | Doses | Age at collection | Outcome |
|-----------------|---------------|---------------|-----------------------|---|--------------------------------------|--------------------------|---------------------------------------|
| Tyl et al. 2008 | Mouse | CD-1 | Dietary exposure | Gestational exposure: F0: 8 weeks pre-breed, GD1-GD14 | 0.003, 0.03, 0.3, 5, 50, 600mg/kg | PND1/birth | No adverse sexual function effects |
| Tyl et al. 2008 | Mouse | CD-1 | Dietary exposure | Postnatal exposure: F1: 8 weeks pre-breed | 0.003, 0.03, 0.3, 5, 50, 600mg/kg | PND1/birth | No adverse sexual function effects |

F1=first filial generation; F2=second filial generation; F3=third filial generation; GD=gestation day; PND=postnatal day

References

- Adewale HB, Jefferson WN, Newbold RR, Patisaul HB. 2009. Neonatal bisphenol-A exposure alters rat reproductive development and ovarian morphology without impairing activation of gonadotropin-releasing hormone neurons. *Biol Reprod* 81:690-699.
- Aghajanova L, Giudice LC. 2011. Effect of bisphenol A on human endometrial stromal fibroblasts *in vivo*. *Reprod Biomed Online* 22:249-256.
- Aldad TS, Rahmani N, Leranath C, Taylor HS. 2011. Bisphenol-A exposure alters endometrial progesterone receptor expression in the nonhuman primate. *Fertil Steril* 96:175-179.
- An BS, Ahn HJ, Kang HS, Jung EM, Yang H, Hong EJ, Jeung EB. 2013. Effects of estrogen and estrogenic compounds, 4-tert-octylphenol, and bisphenol A on the uterine contraction and contraction-associated proteins in rats. *Mol Cell Endocrinol* 375:27-34.
- Anjum S, Rahman S, Kaur M, Ahmad F, Rashid H, Ansari Ra, Raisuddin S. 2011. Melatonin ameliorates bisphenol A-induced biochemical toxicity in testicular mitochondria of mouse. *Food Chem Toxicol* 49:2849-54.
- Arase S, Ishii K, Igarashi K, Aisaki K, Yoshio Y, Matsushima A, et al. 2011. Endocrine disrupter bisphenol A increases *in situ* estrogen production in the mouse urogenital sinus. *Biol Reprod* 84(4):734-42.
- Benachour N, Aris A. 2009. Toxic effects of low doses of Bisphenol-A on human placental cells. *Toxicol Appl Pharmacol* 241:322-328.
- Berger RG, Shaw J, deCatanzaro D. 2008. Impact of acute bisphenol-A exposure upon intrauterine implantation of fertilized ova and urinary levels of progesterone and 17beta-estradiol. *Reprod Toxicol* 26:94-99.
- Berger RG, Foster WG, DeCatanzaro D. 2010. Bisphenol-A exposure during the period of blastocyst implantation alters uterine morphology and perturbs measures of estrogen and progesterone receptor expression in mice. *Reprod Toxicol* 30:393-400.
- Bloom MS, Kim D, vom Saal FS, Taylor JA, Cheng G, Lamb JD et al. 2011a. Bisphenol A exposure reduces the estradiol response to gonadotropin stimulation during *in vivo* fertilization. *Fertil Steril* 96:672-677.
- Bloom MS, vom Saal FS, Kim D, Taylor JA, Lamb JD, Fujimoto VY. 2011b. Serum unconjugated bisphenol A concentrations in men may influence embryo quality indicators during *in vivo* fertilization. *Environ Toxicol Pharmacol* 32:319-323.
- Bosquiazzo VL, Varayoud J, Munoz-de-Toro M, Luque EH, Ramos JG. 2010. Effects of neonatal exposure to bisphenol A on steroid regulation of vascular endothelial growth factor expression and endothelial cell proliferation in the adult rat uterus. *Biol Reprod* 82:86-95.

- Bredhult C, Sahlin L, Olovsson M. 2009. Gene expression analysis of human endometrial endothelial cells exposed to Bisphenol A. *Reprod Toxicol* 28:18-25.
- Briño-Enriquez MA, Robles P, Camats-Tarruella N, Garcia-Cruz R, Roig I, Cabero L et al. 2011a. Human meiotic progression and recombination are affected by bisphenol A exposure during *in vivo* human oocyte development. *Hum Reprod* 26:2807-2818.
- Briño-Enriquez MA, Reig-Viader R, Cabero L, Toran N, Martinez F, Roig I, et al. 2011b. Gene expression is altered after bisphenol A exposure in human fetal oocytes *in vivo*. *Mol Hum Reprod* 2012; 18:171-183.
- Bromer JG, Zhou Y, Taylor MB, Doherty L, Taylor HS. 2010. Bisphenol-A exposure in utero leads to epigenetic alterations in the developmental programming of uterine estrogen response. *FASEB J* 2010; 24:2273-2280.
- Buck Louis GM, Peterson CM, Chen Z, Croughan M, Sundaram R, Stanford J et al. 2013. Bisphenol A and phthalates and endometriosis: the Endometriosis: Natural History, Diagnosis and Outcomes Study. *Fertil Steril* 100:162-9.
- Cabaton NJ, Wadia PR, Rubin BS, Zalko D, Schaeberle CM, Askenase MH, et al. 2011. Perinatal exposure to environmentally relevant levels of bisphenol A decreases fertility and fecundity in CD-1 mice. *Environ Health Perspect* 119:547-552.
- Cantonwine D, Meeker JD, Hu H, Sanchez BN, Lamadrid-Figueroa H, Mercado-Garcia A, et al. 2010. Bisphenol A exposure in Mexico City and risk of prematurity: a pilot nested case control study. *Environ Health* 9:62.
- Castro B, Sanchez P, Torres JM, Preda O, del Moral RG, Ortega E. 2013. Bisphenol A exposure during adulthood alters expression of aromatase and 5alpha-reductase isozymes in rat prostate. *PLoS One* 8(2):e55905.
- Chao HH, Zhang XF, Chen B, Pan B, Zhang LJ, Li L, et al. 2012. Bisphenol A exposure modifies methylation of imprinted genes in mouse oocytes via the estrogen receptor signaling pathway. *Histochem Cell Biol* 137:249-259.
- Chitra KC, Latchoumycandane C, Mathur PP. 2003. Induction of oxidative stress by bisphenol A in the epididymal sperm of rats. *Toxicology* 185:119-27.
- Chou WC, Chen JL, Lin CF, Chen YC, Shih FC, Chuang CY. 2011. Biomonitoring of bisphenol A concentrations in maternal and umbilical cord blood in regard to birth outcomes and adipokine expression: a birth cohort study in Taiwan. *Environ Health* 10:94.

- Cobellis L, Colacurci N, Trabucco E, Carpentiero C, Grumetto L. 2009. Measurement of bisphenol A and bisphenol B levels in human blood sera from healthy and endometriotic women. *Biomed. Chromatogr* 2009; 23:1186-1190.
- D'Cruz SC, Jubendradass R, Jayakanthan M, Rani SJ, Mathur PP. 2012a. Bisphenol A impairs insulin signaling and glucose homeostasis and decreases steroidogenesis in rat testis: an *in vivo* and *in silico* study. *Food Chem Toxicol* 50(3-4):1124-33.
- D'Cruz SC, Jubendradass R, Mathur PP. 2012b. Bisphenol A induces oxidative stress and decreases levels of insulin receptor substrate 2 and glucose transporter 8 in rat testis. *Reprod Sci* 19:163-172.
- DeCatanzaro D, Berger RG, Guzzo AC, Thorpe JB, Khan A. 2013. Perturbation of male sexual behavior in mice (*Mus musculus*) within a discrete range of perinatal bisphenol-A doses in the context of a high- or low-phytoestrogen diet. *Food Chem Toxicol* 55:164-171.
- De Flora S, Micale RT, La Maestra S, Izzotti A, D'Agostini F, Camoirano A, et al. 2011. Upregulation of clusterin in prostate and DNA damage in spermatozoa from bisphenol A-treated rats and formation of DNA adducts in cultured human prostatic cells. *Toxicol Sci* 122:45-51.
- Dobrzynska MM, Radzikowska J. 2013. Genotoxicity and reproductive toxicity of bisphenol A and X-ray/bisphenol A combination in male mice. *Drug Chem Toxicol* 36:19-26.
- Ehrlich S, Williams PL, Missmer SA, Flaws JA, Ye X, Calafat AM et al. 2012a. Urinary bisphenol A concentrations and early reproductive health outcomes among women undergoing IVF. *Hum. Reprod* 27:3583-3592.
- Ehrlich S, Williams PL, Missmer SA, Flaws JA, Berry KF, Calafat AM, et al. 2012b. Urinary Bisphenol A concentrations and implantation failure among women undergoing *in vitro* fertilization. *Environ Health Perspect* 120(7):978-83.
- Ehrlich S, Williams PL, Hauser R, Missmer SA, Peretz J, Calafat AM, Flaws JA. 2013. Urinary bisphenol A concentrations and cytochrome P450 19 A1 (*Cyp19*) gene expression in ovarian granulosa cells: an *in vivo* human study. *Reprod Toxicol* 42:18-23.
- Eichenlaub-Ritter U, Vogt E, Cukurcam S, Sun F, Pacchierotti F, Parry J. 2008. Exposure of mouse oocytes to bisphenol A causes meiotic arrest but not aneuploidy. *Mutat Res* 651:82-92.
- El Beshbishy HA, Aly HA, El Shafey M. 2012. Lipoic acid mitigates bisphenol A-induced testicular mitochondrial toxicity in rats. *Toxicol Ind. Health* DOI: 10.1177/0748233712446728.
- Environmental Protection Agency (EPA). Integrated Risk Information Systems: Bisphenol A (CASRN 80-05-7). Updated 07/01/1993. <http://www.epa.gov/iris/subst/0356.htm#bib>.

- Fang Y, Zhou Y, Zhong Y, Gao X, Tan T. 2013. Effect of vitamin E on reproductive functions and anti-oxidant activity of adolescent male mice exposed to bisphenol A. *Wei Sheng Yan Jiu* 42:18-22.
- Fenichel P, Dechaux H, Harthe C, Gal J, Ferrari P, Pacini P, et al. 2012. Unconjugated bisphenol A cord blood levels in boys with descended or undescended testes. *Hum Reprod* 27:983-990.
- Fernandez M, Bianchi M, Lux-Lantos V, Libertun C. 2009. Neonatal exposure to bisphenol A alters reproductive parameters and gonadotropin releasing hormone signaling in female rats. *Environ Health Perspect* 117:757-762.
- Fernandez M, Bourguignon N, Lux-Lantos V, Libertun C. 2010. Neonatal exposure to bisphenol A and reproductive and endocrine alterations resembling the polycystic ovarian syndrome in adult rats. *Environ Health Perspect* 118:1217-1222.
- Fujimoto VY, Kim D, vom Saal FS, Lamb JD, Taylor JA, Bloom MS. 2011. Serum unconjugated bisphenol A concentrations in women may adversely influence oocyte quality during *in vivo* fertilization. *Fertil Steril* 95:1816-1819.
- Galloway T, Cipelli R, Guralnik J, Ferrucci L, Bandinelli S, Corsi AM, et al. 2010. Daily bisphenol A excretion and associations with sex hormone concentrations: results from the InCHIANTI adult population study. *Environ Health Perspect* 118:1603-1608.
- Gayraud V, Lacroix MZ, Collet SH, Viguie C, Bousquet-Melou A, Toutain PL, Picard-Hagen N. 2013. High bioavailability of bisphenol A from sublingual exposure. *Environ Health Perspect* 121:951-6.
- Grasselli F, Baratta L, Baioni L, Bussolati S, Ramoni R, Grolli S, et al. 2010. Bisphenol A disrupts granulosa cell function. *Domest. Anim Endocrinol* 39:34-39.
- Hampton T. 2013. NIH panel: Name change, new priorities advised for polycystic ovary syndrome. *JAMA* 309:863.
- Hiyama M, Choi EK, Wakitani S, Tachibana T, Khan H, Kusakabe KT, et al. 2011. Bisphenol-A (BPA) affects reproductive formation across generations in mice. *J Vet Med Sci* 73:1211-1215.
- Horstman KA, Naciff JM, Overmann GJ, Foertsch LM, Richardson BD, Daston GP. 2012. Effects of transplacental 17- α -ethynyl estradiol or bisphenol A on the developmental profile of steroidogenic acute regulatory protein in the rat testis. *Birth Defects Res B Dev Reprod Toxicol* 95(4):318-25.
- Howdeshell KL, Furr J, Lambright CR, Wilson VS, Ryan BC, Gray LE, Jr. 2008. Gestational and lactational exposure to ethynyl estradiol, but not bisphenol A, decreases androgen-dependent reproductive organ weights and epididymal sperm abundance in the male Long Evans hooded rat. *Toxicol Sci* 102:371-382.

- Hunt PA, Koehler KE, Susiarjo M, Hodges CA, Illagan A, Voigt RC, et al. 2003. Bisphenol A exposures causes meiotic aneuploidy in the female mouse. *Curr Biol* 13:546-53.
- Hunt PA, Susiarjo M, Rubio C, Hassold TJ. 2009. The bisphenol A experience: a primer for the analysis of environmental effects on mammalian reproduction. *Biol Reprod* 81(5):807-13.
- Hunt PA, Lawson C, Gieske M, Murdoch B, Smith H, Marre A, et al. 2012. Bisphenol A alters early oogenesis and follicle formation in the fetal ovary of the rhesus monkey. *Proc Natl Acad Sci U. S. A.* 109:17525-17530.
- Iguchi T, Fukazawa Y, Uesugi Y, Taksugi N. 1990. Polyovular follicles in mouse ovaries exposed neonatally to diethylstilbestrolin vivo and in vitro. *Biol Reprod* 43 478–484.
- Jin P, Wang X, Chang F, Bai Y, Li Y, Zhou R, Chen L. 2013. Low dose bisphenol A impairs spermatogenesis by suppressing reproductive hormone production and promoting germ cell apoptosis in adult rats. *J Biomed Res* 27:135-144.
- Kabuto H, Hasuike S, Minagawa N, Shishibori T. 2003. Effects of bisphenol A on the metabolisms of active oxygen species in mouse tissues. *Environ Res* 93:31-5.
- Kabuto H, Amakawa M, Shishibori T. 2004. Exposure to bisphenol A during embryonic/fetal life and infancy increases oxidative injury and cause underdevelopment of the brain and testes in mice. *Life Sci* 30:2931-40.
- Kandaraki E, Chatzigeorgiou A, Livadas S, Palioura E, Economou F, Koutsilieris M, et al. 2011. Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. *J Clin Endocrinol Metab* 96:E480-E484.
- Kobayashi K, Kubota H, Ohtani K, Hojo R, Miyagawa M. 2012. Lack of effects for dietary exposure of bisphenol A during in utero and lactational periods on reproductive development in rat offspring. *J Toxicol Sci* 37:565-573.
- Kobayashi K, Ohtani K, Kubota H, Miyagawa M. 2010. Dietary exposure to low doses of bisphenol A: effects on reproduction and development in two generations of C57BL/6J mice. *Congenit. Anom. (Kyoto)* 50:159-170.
- LaRocca J, Boyajian A, Brown C, Smith SD, Hixon M. 2011. Effects of in utero exposure to Bisphenol A or diethylstilbestrol on the adult male reproductive system. *Birth Defects Res B Dev. Reprod Toxicol* 92:526-533.
- Lawson C, Gieske M, Murdoch B, Ye P, Li Y, Hassold T, et al. 2011. Gene expression in the fetal mouse ovary is altered by exposure to low doses of bisphenol A. *Biol Reprod* 84:79-86.

- Lee BE, Park H, Hong YC, Ha M, Kim Y, Chang N, Kim BN, Kim YJ, Yu SD, Ha EH. 2013. Prenatal bisphenol A and birth outcomes: MOCEH (Mothers and Children's Environmental Health) study. *Int J Hyg Environ Health*. pii: S1438-4639(13)00099-0. doi: 10.1016/j.ijheh.2013.07.005.
- Lee SG, Kim JY, Chung JY, Kim YJ, Park JE, Oh S, Yoon YD, Yoo KS, Yoo YH, Kim JM. 2013. Bisphenol A exposure during adulthood causes augmentation of follicular atresia and luteal regression by decreasing 17beta-estradiol synthesis via downregulation of aromatase in rat ovary. *Environ Health Perspect* 121:663-669.
- Lee SH, Kang SM, Choi MH, Lee J, Park MJ, Kim SH, Lee WY, Hong J, Chung BC. 2013. Changes in steroid metabolism among girls with precocious puberty may not be associated with urinary levels of bisphenol A. *Reprod Toxicol*. doi:10.1016/j.reprotox.2013.03.008.
- Lenie S, Cortvrindt R, Eichenlaub-Ritter U, Smits J. 2008. Continuous exposure to bisphenol A during *in vivo* follicular development induces meiotic abnormalities. *Mutat Res* 651:71-81.
- Li DK, Zhou Z, Qing D, He Y, Wu T, Miao M, et al. 2010. Occupational exposure to bisphenol-A (BPA) and the risk of self-reported male sexual dysfunction. *Hum. Reprod* 25:519-527.
- Li DK, Zhou Z, Miao M, He Y, Wang J, Ferber J, et al. 2011. Urine bisphenol-A (BPA) level in relation to semen quality. *Fertil Steril* 95:625-630.
- Li Y, Zhang W, Liu J, Wang W, Li H, Zhu J, Weng S, Xiao S, Wu T. 2013. Prepubertal bisphenol A exposure interferes with ovarian follicle development and its relevant gene expression. *Reprod Toxicol*. pii: S0890-6238(13)00348-1. doi:10.1016/j.reprotox.2013.09.002.
- Li YJ, Song TB, Cai YY, Zhou JS, Song X, Zhao X, et al. 2009. Bisphenol A exposure induces apoptosis and upregulation of Fas/FasL and caspase-3 expression in the testes of mice. *Toxicol Sci* 108(2):427-36.
- Liu C, Duan W, Li R, Xu S, Zhang L, Chen C, He M, Lu Y, Wu H, Pi H, Luo X, Zhang Y, Zhong M, Yu Z, Zhou Z. 2013. Exposure to bisphenol A disrupts meiotic progression during spermatogenesis in adult rats through estrogen-like activity. *Cell Death Dis* 4:e676.
- Machtiger R, Combelles CM, Missmer SA, Correia KF, Williams P, Hauser R, Racowsky C. 2013. Bisphenol-A and human oocyte maturation *in vitro*. *Hum Reprod* 28:2735-45.
- Meeker JD, Calafat AM, Hauser R. 2010a. Urinary bisphenol A concentrations in relation to serum thyroid and reproductive hormone levels in men from an infertility clinic. *Environ Sci Technol* 44:1458-1463.
- Meeker JD, Ehrlich S, Toth TL, Wright DL, Calafat AM, Trisini AT, et al. 2010b. Semen quality and sperm DNA damage in relation to urinary bisphenol A among men from an infertility clinic. *Reprod Toxicol* 30:532-539.

- Mendiola J, Jorgensen N, Andersson AM, Calafat AM, Ye X, Redmon JB et al. 2010. Are environmental levels of bisphenol A associated with reproductive function in fertile men? *Environ Health Perspect* 118:1286-1291.
- Mendoza-Rodriguez CA, Garcia-Guzman M, Baranda-Avila N, Morimoto S, Perrot-Appianat M, Cerbon M. 2011. Administration of bisphenol A to dams during perinatal period modifies molecular and morphological reproductive parameters of the offspring. *Reprod Toxicol* 31:177-183.
- Miao M, Yuan W, He Y, Zhou Z, Wang J, Gao E, et al. 2011a. In utero exposure to bisphenol-A and anogenital distance of male offspring. *Birth Defects Res A Clin Mol Teratol* 91:867-872.
- Miao M, Yuan W, Zhu G, He X, Li DK. 2011b. In utero exposure to bisphenol-A and its effect on birth weight of offspring. *Reprod Toxicol* 32:64-68.
- Minamiyama Y, Ichikawa H, Takemura S, Kusunoki H, Naito Y, Yoshikawa T. 2010. Generation of reactive oxygen species in sperms of rats as an earlier marker for evaluating the toxicity of endocrine-disrupting chemicals. *Free Radic Res* 44(12):1398-406.
- Mok-Lin E, Ehrlich S, Williams PL, Petrozza J, Wright DL, Calafat AM, et al. 2010. Urinary bisphenol A concentrations and ovarian response among women undergoing IVF. *Int J Androl* 33:385-393.
- Morice L, Benaitreau D, Dieudonne MN, Morvan C, Serazin V, de Mazancourt P, et al. 2011. Antiproliferative and proapoptotic effects of bisphenol A on human trophoblastic JEG-3 cells. *Reprod Toxicol* 32:69-76.
- Muhlhauser A, Susiarjo M, Rubio C, Griswold J, Gorence G, Hassold T, et al. 2009. Bisphenol A Effects on the Growing Mouse Oocyte Are Influenced by Diet. *Biol Reprod* 80:1067–1072. DOI: 10.1095/biolreprod.108.074815
- Nah WH, Park MJ, Gye MC. 2011. Effects of early prepubertal exposure to bisphenol A on the onset of puberty, ovarian weights, and estrous cycle in female mice. *Clin Exp Reprod Med* 38:75-81.
- Nakamura D, Yanagiba Y, Duan Z, Ito Y, Okamura A, Asaeda N, et al. 2010. Bisphenol A may cause testosterone reduction by adversely affecting both testis and pituitary systems similar to estradiol. *Toxicol Lett* 194:16-25.
- Nanjappa MK, Simon L, Akingbemi BT. 2012. The industrial chemical bisphenol A (BPA) interferes with proliferative activity and development of steroidogenic capacity in rat Leydig cells. *Biol Reprod* 86(5):135,1-12.

- Newbold RR, Jefferson WN, Padilla-Banks E. 2009. Prenatal exposure to bisphenol a at environmentally relevant doses adversely affects the murine female reproductive tract later in life. *Environ Health Perspect* 117:879-885.
- Nicholson TM, Ricke EA, Marker PC, Miano JM, Mayer RD, Timms BG, et al. 2012. Testosterone and 17beta-estradiol induce glandular prostatic growth, bladder outlet obstruction, and voiding dysfunction in male mice. *Endocrinology* 153(11):5556-65.
- Nicholson TM, Ricke WA. 2011. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. *Differentiation* 82(4-5):184-99.
- N'Tumba-Byn T, Moison D, Lacroix M, Lecureuil C, Lesage L, Prud'homme SM, Pozzi-Gaudin S, Frydman R, Benachi A, Livera G, Rouiller-Fabre V, Habert R. 2013. Differential effects of bisphenol A and diethylstilbestrol on human, rat and mouse fetal Leydig cell function. *PLoS One*. 7(12):e51579. doi: 10.1371/journal.pone.0051579.
- Okada A, Kai O. 2008. Effects of estradiol-17beta and bisphenol A administered chronically to mice throughout pregnancy and lactation on the male pups' reproductive system. *Asian J Androl* 10:271-276.
- Pacchierotti F, Ranaldi R, Eichenlaub-Ritter U, Attia S, Adler ID. 2008. Evaluation of aneugenic effects of bisphenol A in somatic and germ cells of the mouse. *Mutat Res* 651:64-70.
- Padmanabhan V, Siefert K, Ransom S, Johnson T, Pinkerton J, Anderson L, et al. 2008. Maternal bisphenol-A levels at delivery: a looming problem? *J Perinatol* 28:258-263.
- Peretz J, Gupta RK, Singh J, Hernandez-Ochoa I, Flaws JA. 2011. Bisphenol A impairs follicle growth, inhibits steroidogenesis, and downregulates rate-limiting enzymes in the estradiol biosynthesis pathway. *Toxicol Sci* 119:209-217.
- Peretz J, Craig ZR, Flaws JA. 2012. Bisphenol A inhibits follicle growth and induces atresia in cultured mouse antral follicles independently of the genomic estrogenic pathway. *Biol Reprod* 87(3):63.
- Philippat C, Mortamais M, Chevrier C, Petit C, Calafat AM, Ye X, Silva MJ, Brambilla C, Pin I, Charles MA, Cordier S, Slama R. 2012. Exposure to phthalates and phenols during pregnancy and offspring size at birth. *Environ Health Perspect*. 120(3):464-70
- Prins GS, Ye SH, Birch L, Ho SM, Kannan K. 2011. Serum bisphenol A pharmacokinetics and prostate neoplastic responses following oral and subcutaneous exposures in neonatal Sprague-Dawley rats. *Reprod Toxicol* 31:1-9.
- Qiao L, Zheng L, Cai D. 2010. Study on the levels of the bisphenol A, octylphenol, 4-nonylphenol in serum of precocious girls. *Wei Sheng Yan Jiu* 39(1):9-12.

- Qiu LL, Wang X, Zhang XH, Zhang Z, Gu J, Liu L, Wang Y, Wang X, Wang SL. 2013. Decreased androgen receptor expression may contribute to spermatogenesis failure in rats exposed to low concentration of bisphenol A. *Toxicol Lett* 219:116-124.
- Rashid H, Ahmad F, Rahman S, Ansari Ra, Bhatia K, Kaur M, Islam F, Raisuddin S. 2009. Iron deficient augments bisphenol A-induced oxidative stress in rats. *Toxicology* 256:7-12.
- Richter CA, Birnbaum LS, Farabollini F, Newbold RR, Rubin BS, Talsness CE, Vandenberg JG, Walser-Kuntz DR, vom Saal FS. 2007. *In vivo* effects of bisphenol A in laboratory rodent studies. *Reprod Toxicol*. 24(2):199-224.
- Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP. 2008. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. *FASEB J* 22(5):1512-20.
- Rivera OE, Varayoud J, Rodriguez HA, Munoz-de-Toro M, Luque EH. 2011. Neonatal exposure to bisphenol A or diethylstilbestrol alters the ovarian follicular dynamics in the lamb. *Reprod Toxicol* 32:304-312.
- Rodriguez HA, Santambrosio N, Santamaria CG, Munoz-de-Toro M, Luque EH. 2010. Neonatal exposure to bisphenol A reduces the pool of primordial follicles in the rat ovary. *Reprod Toxicol* 2010; 30:550-557.
- Ross C, Morriss A, Khairy M, Khalaf Y, Braude P, Coomarasamy A, et al. 2010. A systematic review of the effect of oral antioxidants on male infertility. *Reprod Biomed Online* 20(6):711-23.
- Ryan BC, Hotchkiss AK, Crofton KM, Gray LE, Jr. 2010. In utero and lactational exposure to bisphenol A, in contrast to ethinyl estradiol, does not alter sexually dimorphic behavior, puberty, fertility, and anatomy of female LE rats. *Toxicol Sci* 114:133-148.
- Salian S, Doshi T, Vanage G. 2009a. Neonatal exposure of male rats to bisphenol A impairs fertility and expression of Sertoli cell junctional proteins in the testis. *Toxicology* 265:56-67.
- Salian S, Doshi T, Vanage G. 2009b. Perinatal exposure of rats to bisphenol A affects the fertility of male offspring. *Life Sci* 85:742-752.
- Sánchez P, Castro B, Torres JM, Olmo A, Del Moral RG, Ortega E. 2013. Bisphenol A modifies the regulation exerted by testosterone on 5 α -reductase isozymes in ventral prostate of adult rats. *Biomed Res Int*. 2013:629235. doi:10.1155/2013/629235.
- Signorile PG, Spugnini EP, Mita L, Mellone P, D'Avino A, Bianco M, et al. 2010. Pre-natal exposure of mice to bisphenol A elicits an endometriosis-like phenotype in female offspring. *Gen Comp Endocrinol* 168:318-325.

- Snijder CA, Heederik D, Pierik FH, Hofman A, Jaddoe VW, Koch HM, Longnecker MP, Burdorf A. 2013. Fetal growth and prenatal exposure to bisphenol A: The generation R study. *Environ Health Perspect*. 121(3):393-8. doi:10.1289/ehp.1205296.
- Susiarjo M, Hassold TJ, Freeman E, Hunt PA. 2007. Bisphenol A exposure in utero disrupts early oogenesis in the mouse. *PLoS Genet* 12;3(1):e5.
- Susiarjo M, Sasson I, Mesaros C, Bartolomei MS. 2013. Bisphenol A exposure disrupts genomic imprinting in the mouse. *PLoS Genet* 9(4):e1003401. doi:10.1371/journal.pgen.1003401.
- Tainaka H, Takahashi H, Umezawa M, Tanaka H, Nishimune Y, Oshio S, et al. 2012. Evaluation of the testicular toxicity of prenatal exposure to bisphenol A based on microarray analysis combined with MeSH annotation. *J Toxicol Sci* 37:539-548.
- Tan W, Huang H, Wang Y, Wong TY, Wang CC, Leung LK. 2013. Bisphenol A differentially activates protein kinase C isoforms in murine placental tissue. *Toxicol Appl Pharmacol*. 269(2):163-8. doi:10.1016/j.taap.2013.03.016.
- Tang WY, Morey LM, Cheung YY, Birch L, Prins GS, Ho SM. 2012. Neonatal exposure to estradiol/bisphenol A alters promoter methylation and expression of Nsbp1 and Hpcal1 genes and transcriptional programs of Dnmt3a/b and Mbd2/4 in the rat prostate gland throughout life. *Endocrinology* 153(1):42-55.
- Thuillier R, Manku G, Wang Y, Culty M. 2009. Changes in MAPK pathway in neonatal and adult testis following fetal estrogen exposure and effects on rat testicular cells. *Microsc Res Tech* 72:773-786.
- Tiwari D, Vanage G. 2013. Mutagenic effect of Bisphenol A on adult rat male germ cells and their fertility. *Reprod Toxicol*.40:60-8. doi: 10.1016/j.reprotox.2013.05.013.
- Trapphoff T, Heiligentag M, El Hajj N, Haaf T, Eichenlaub-Ritter U. 2013. Chronic exposure to a low concentration of bisphenol A during follicle culture affects the epigenetic status of germinal vesicles and metaphase II oocytes. *Fertil Steril*. pii: S0015-0282(13)02968-3. doi: 10.1016/j.fertnstert.2013.08.021.
- Tyl RW, Myers CB, Marr MC, Sloan CS, Castillo NP, Veselica MM, et al. 2008. Two-generation reproductive toxicity study of dietary bisphenol A in CD-1 (Swiss) mice. *Toxicol Sci* 104:362-384.
- Vandenberg LN, Chahoud I, Heindel JJ, Padmanabhan V, Paumgartten FJ, Schoenfelder G. 2010. Urinary, circulating, and tissue biomonitoring studies indicate widespread exposure to bisphenol A. *Environ Health Perspect* 118:1055-70.
- Vandenberg LN, Ehrlich S, Belcher SM, Ben-Jonathan N, Dolinoy Dc, Hugo ER, Hunt PA, Rubin BS, Saili KS, Soto AM, Wang H-S, vom Saal FS. 2013. Low dose effects of bisphenol A: An integrated review of *in vitro*, laboratory animal, and epidemiology studies. *Endocrine Disruptors* 1:1e25078.

- Varayoud J, Ramos JG, Bosquiazzo VL, Lower M, Munoz-de-Toro M, Luque EH. 2011. Neonatal exposure to bisphenol A alters rat uterine implantation-associated gene expression and reduces the number of implantation sites. *Endocrinology* 152:1101-1111.
- Varayoud J, Ramos JG, Bosquiazzo VL, Munoz-de-Toro M, Luque EH. 2008. Developmental exposure to bisphenol A impairs the uterine response to ovarian steroids in the adult. *Endocrinology* 149:5848-5860.
- Veiga-Lopez A, Luense LJ, Christenson LK, Padmanabhan V. 2013. Developmental programming: gestational bisphenol-A treatment alters trajectory of fetal ovarian gene expression. *Endocrinology*. 154(5):1873-84.
- vom Saal FS, Akingbemi BT, Belcher SM, Birnbaum LS, Crain DA, Eriksen M, et al. 2007. Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. *Reprod Toxicol* 24:131-138.
- vom Saal FS, VandeVoort C, Taylor J, Welshons W, Toutain P-L, Hunt PA. 2014. Bisphenol A (BPA) pharmacokinetics with daily oral bolus or continuous exposure via silastic capsules in pregnant rhesus monkeys:relevance for human exposures. *Reprod Toxicol*, in press.
<http://dx.doi.org/10.1016/j.reprotox.2014.01.007>
- Wang Q, Zhao XF, Ji YL, Wang H, Liu P, Zhang C, et al. 2010. Mitochondrial signaling pathway is also involved in bisphenol A induced germ cell apoptosis in testes. *Toxicol Lett* 199(2):129-35.
- Wang Z, Liu BC, Lin GT, Lin CS, Lue TF, Willingham E, et al. 2007. Up-regulation of estrogen responsive genes in hypospadias: microarray analysis. *J Urol* 177(5):1939-46.
- Willingham E, Baskin LS. 2007. Candidate genes and their response to environmental agents in the etiology of hypospadias. *Nat Clin Pract Urol* 4(5):270-9.
- Wolff MS, Britton JA, Boguski L, Hochman S, Maloney N, Serra N, Liu Z, Berkowitz G, Larson S, Forman J. 2008a. Environmental exposures and puberty in inner-city girls. *Environ Res* 107(3):393-400.
- Wolff MS, Engel SM, Berkowitz GS, Ye X, Silva MJ, Zhu C, Wetmur J, Calafat AM. 2008b. Prenatal phenol and phthalate exposures and birth outcomes. *Environ Health Perspect*. 116(8):1092-7.
- Wolff MS, Teitelbaum SL, Pinney SM, Windham G, Liao L, Biro F, Kushi LH, Erdmann C, Hiatt RA, Rybak ME, Calafat AM; Breast Cancer and Environment Research Centers. 2010. Investigation of relationships between urinary biomarkers of phytoestrogens, phthalates, and phenols and pubertal stages in girls. *Environ Health Perspect*. 118(7):1039-46.
- Wu HJ, Liu C, Duan WX, Xu SC, He MD, Chen CH, Wang Y, Zhou Z, Yu ZP, Zhang L, Chen Y. 2013. Melatonin ameliorates bisphenol A-induced DNA damage in the germ cells of adult male rats. *Mutat Res* 752:57-67.

- Wu JH, Jiang XR, Liu GM, Liu XY, He GL, Sun ZY. 2011. Oral exposure to low-dose bisphenol A aggravates testosterone-induced benign hyperplasia prostate in rats. *Toxicol Ind Health* 27:810-819.
- Xi W, Lee CK, Yeung WS, Giesy JP, Wong MH, Zhang X, et al. 2011. Effect of perinatal and postnatal bisphenol A exposure to the regulatory circuits at the hypothalamus-pituitary-gonadal axis of CD-1 mice. *Reprod Toxicol* 31:409-417.
- Xiao S, Diao H, Smith MA, Song X, Ye X. 2011. Preimplantation exposure to bisphenol A (BPA) affects embryo transport, preimplantation embryo development, and uterine receptivity in mice. *Reprod Toxicol* 32:434-441.
- Yigit F, Daglioglu S. 2010. Histological changes in the uterus of the hens after embryonic exposure to bisphenol A and diethylstilbestrol. *Protoplasma* 247:57-63.
- Zhang HQ, Zhang XF, Zhang LJ, Chao HH, Pan B, Feng YM, et al. 2012. Fetal exposure to bisphenol A affects the primordial follicle formation by inhibiting the meiotic progression of oocytes. *Mol Biol Rep* 39:5651-5657.
- Zhang XF, Zhang LJ, Feng YN, Chen B, Feng YM, Liang GJ, et al. 2012. Bisphenol A exposure modifies DNA methylation of imprint genes in mouse fetal germ cells. *Mol Biol Rep* 39:8621-8628.
- Zhou W, Liu J, Liao L, Han S, Liu J. 2008. Effect of bisphenol A on steroid hormone production in rat ovarian theca-interstitial and granulosa cells. *Mol Cell Endocrinol* 283:12-18.
- Ziv-Gal A, Craig ZR, Wang W, Flaws JA. 2013. Bisphenol A inhibits cultured mouse ovarian follicle growth partially via the aryl hydrocarbon receptor signaling pathway. *Reprod Toxicol*. 42C:58-67. doi:10.1016/j.reprotox.2013.07.022.